PRESS RELEASE
NOTEBOOK
Stéphane Thiroloix, new Polepharma President
Stéphane Thiroloix, CEO of Mayoly Spindler, an independent French and international pharmaceutical company and benchmark company in the field of gastroenterology and dermocosmetics, was elected President on Monday, 4 July 2016 by Polepharma’s Board of Directors.

He succeeds Guillaume Clément, President of LEO Pharma France, after three years of service.

Stéphane Thiroloix graduated from the École des Hautes Études Commerciales (HEC) [Paris Business School] and began his career at Roussel Uclaf (now Sanofi), where, for 11 years, he held roles in Marketing/Sales and General Management in South Africa, Mexico, Australia and France.

He continued his career at SmithKline Beecham (GlaxoSmithKline), where he was appointed Vice-President and Director of French Operations, and then Vice-President, Europe, Business Development and Marketing Alliances.

From 2002 to 2007, he was Vice-President of French Operations and then became Vice-President, Europe, and General Manager, France, at Bristol-Myers Squibb.

In 2007, he joined the executive committee at the Ipsen Group, a global biopharmaceutical company headquartered in France, as Executive VP, where he was in charge of Corporate Development (Business dDt and Legal Affairs, Pre-clinical and Clinical Development, Regulatory Affairs).

Before joining Laboratoires Mayoly Spindler, Stéphane Thiroloix had been working since 2011 as President, Europe, Canada, Japan and Australia, of the Advanced Surgical Devices (ASD) Division at Smith & Nephew.

Polepharma press contact: Caroline VILLEDIEU – 02 37 20 24 24 caroline.villedieu@polepharma.com

Mayoly Spindler press contact : Pascal FRUIT – 01 34 80 55 75 Pascal.Fruit@mayoly.com